Tracer library / [131I]I-ERIC1

[131I]I-ERIC1

Also written as [I-131]I-ERIC1

Radionuclide: I-131 t½ 11549 min
Modality: Therapy
Production route: —
Stage: Preclinical
Syntheses indexed: 1

Preclinical only, no clinical indication yet

What it is

Compound class: Anti-NCAM monoclonal antibody (radioimmunoconjugate)
Target / mechanism: Neural cell adhesion molecule (NCAM) PMID 39409066
Clinical application: Neuroblastoma PMID 39409066
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	SPE	50-60%	>95%	ERIC1 antibody	39409066 2024 Int J Mol Sci The antibody ERIC1 (0.1 mg/mL) was radiolabeled with varying activities of 131I using a variant of the chloramine-T method. - The labeling of ERIC1 with I-131 achieved a yield of approximately 50–60%

Need this precursor?We can point you to suppliers for [131I]I-ERIC1, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 39409066. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 39409066: 'The antibody ERIC1 (0.1 mg/mL) was radiolabeled with varying activities of 131I'. Stage set/updated at stage 23 from PMID 39409066: 'Tumoricidal Activity and Side Effects of Radiolabeled Anti-NCAM [131I]-Iodine-ERIC1 in Neuroblastoma-Bearing Mice.'.